Funding and support provided by

APOS PSYCHOSOCIAL
POCKET GUIDE

A quick reference resource for psychosocial professionals

The information contained in this guide does not constitute medical advice and is not intended to replace a healthcare provider’s independent medical judgment regarding the treatment or management of individual patients.

Table of Contents

Financial Distress

Author(s): Fumiko Chino, MD, Fantine Giap, MD
Editor(s): Beth Gardini Dixon, PsyD, Sharla Wells-DiGregorio, PhD

Background

Financial toxicity, defined as the problems a patient has related to the cost of medical care, is a prevalent issue facing patients with cancer and their families today. A recent American Society of Clinical Oncology (ASCO) National Cancer Opinion Survey found that slightly more people were worried about cancer’s financial impact than were worried about death from cancer (57% vs 54%)1. A cancer diagnosis can have lasting effects on both personal and family finances. As the cost of health care rises (with more and more costs being pushed onto patients in the form of rising premiums, copayments, coinsurance, and deductibles), treatment affordability is a growing concern. Even with health insurance, out of pocket expenses can significantly decrease quality of life, patient satisfaction, and symptom burden; financial toxicity can also erode quality of care and cancer outcomes. It is therefore of clinical importance for providers to understand the framework for defining the different aspects of financial toxicity, risk factors, impact, and potential interventions.

 

Impact of Financial Toxicity: Important Terms Defined

  • Objective financial burden: out of pocket expenses (OOPE)
    • Direct OOPE
      • Health insurance costs: premiums (paid monthly), deductible (paid in full before insurance pays anything)
      • Direct medical costs: co-insurance (percentage paid once deductible is met) and co-payments (fixed rate fees) for consultation, imaging, biopsy, surgery, chemotherapy, radiation, hospitalizations, survivorship care, supportive medications, supportive therapies (physical therapy, acupuncture, etc.)
      • Direct non-medical costs: transportation, parking, food, housing/accommodations, child or elder care
    • Indirect OOPE: productivity/income loss for patient and caregivers (missed time from work), time/opportunity loss, early retirement for older patients, decreased educational attainment for young patients
  • Subjective financial burden: physical and psychosocial response to financial toxicity
    • Distress related to cancer and anticipated costs of cancer care
    • Increased symptom burden
    • Decreased physical functioning
    • Decreased social functioning
  • Common coping mechanisms: sacrifices made by both patients and caregivers in order to afford care that can affect financial stability of household, quality of life, and quality of cancer care received
    • Financial coping mechanisms: cutting back on leisure activities, cutting back on food/clothing, using savings, borrowing money from family, bank loans, payment plans, increased credit card debt, avoiding bill payments, selling property, bankruptcy
    • Medical coping mechanisms: skipping or delaying medications, scans, visits, treatment, survivorship care, mental health care

Risk Factors for Financial Toxicity

Knowing risk factors may improve provider awareness of those at highest risk for financial toxicity. These patients may face higher financial burdens and negative repercussions; discussion of financial toxicity should be included in the decision-making process for primary cancer treatment and ongoing survivorship care.

 

Patient Risk Factors

Younger age

·       More likely to not have completed education, have active student loans

·       More likely to have jobs based on hourly wages and less likely to have adequate insurance coverage or paid sick leave

·       Less likely to have significant savings

·       Dependence on parental caregivers

Lower SES

·       More likely to have lower healthy literacy

·       More likely to have difficulty with transportation and lodging

·       Less likely to have adequate insurance coverage or paid sick leave

·       Less likely to able to participate in clinical trials

·       More likely to be living paycheck to paycheck (limited savings or financial cushion for time away from work)

Underinsured or uninsured

·       More likely to be paying OOP for visits, treatment, and supportive medications

·       Limited access to specialty cancer care or supportive services

·       Limited ability to get medications

Unemployment

·       Less likely to have adequate insurance coverage (due to high-cost COBRA plans, or limited coverage via short-term, limited-duration insurance)

·       More likely to be dependent on charity care and financial support

·       Limited income from disability or unemployment benefits

Racial/ethnic minorities

·       More likely to be denied insurance secondary to structural racism

·       More likely face work related barriers (no sick time, limited work allowances)

·       More likely to have transportation barriers

·       Less likely to have access to cancer screening and thus present at more advanced stages requiring more intense treatment

Rural residence

·       Increased barriers to care include increased transportation and lodging costs

·       Limited access to specialty cancer care, supportive services; more difficulties coordinating care

Disease Risk Factors

Cancer Type

·       Cancer types which require multimodality treatment, i.e. surgery, chemotherapy, and radiation

·       Cancer or cancer treatment which causes significant symptom burden which requires time off work and a caregiver

·       Cancer treatments which require prolonged hospitalizations i.e. induction chemotherapy and transplant

Cancer Stage

·       Advanced disease requiring intense treatment and potentially durable side effects causing debility

·       Metastatic disease which may require life-long treatment

Click here to view table as PDF

Negative Effects of Financial Toxicity

As noted above, certain coping behaviors can develop secondary to financial toxicity. It is important to identify these patients during clinical encounters as potential downstream consequences of these behaviors can compromise personal, financial, or family outcomes.

Coping Behavior Behavioral changes due to increased expenses Potential negative personal, financial, or family outcomes
Altering care plan

·       Skipping or delaying treatment

·       Unfilled prescriptions

·       Rationing medication

·       Declined recommended supportive services

·       Delayed or missed appointments

·       Avoidance of recommended procedure/tests

·       Suboptimal treatment leading to treatment gaps, disease recurrence/progression, death

·       Higher physical symptom burden, decreased quality of life

·       Lower quality survivorship care, decreased recovery and poorer long term functioning

Altering lifestyle

·       Decrease in recreational activities

·       Decrease spending on food and other essentials

·       Decreased quality of life

·       Decreased nutrition, increased food insecurity

·       Decreased in overall wellness of the patient and family/caregivers

Altering school/work

·       Dropping out of school/training

·       Early return to work (including during active treatment)

·       Early retirement

·       Decrease to part time work/decreased responsibilities

·       Decreased earning potential and/or limited career growth

·       Decreased ability to recover from treatment if returning too soon, increased exposure to pathogens, delayed recovery

·       Possible loss of employee-based insurance coverage

·       Loss of income/decreased financial stability

Support seeking from others ·       Dependence on family, friends, and community for caregiving, loans, supportive care ·       Caregiver financial, emotional, and physical fatigue

Click here to view table as PDF

Potential Interventions

Financial toxicity has many drivers and thus potential solutions exist within systemic, interpersonal, and individual frameworks. Primary prevention is focused on actions that could be addressed to reduce the overall burden of costs and improve affordability prior to patients presenting for cancer treatment. Secondary prevention focuses on screening and diagnosing financial toxicity early on the cancer care continuum so that assistance can be delivered early. Tertiary prevention is practical advice to address patients already demonstrating financial toxicity.

Level of Intervention Recommendations
Primary Prevention Health Policy Value based care

·       Advocate for alternative payment models that incorporate both quality care delivery metrics and patient affordability concerns

·       Increased price transparency

Clinical Infrastructure Financial navigation

·       Formal training of financial navigators

·       Patient training for communicating with insurance companies

·       Patient paperwork assistance

·       Partnering with community resources to address social influencers of health, support groups, financial tools

Clinical-financial pathways ·       Institutionalize multi-disciplinary clinical roadmaps that include financial responsibilities prior to, during and after primary cancer management
Limit indirect costs

·       Parking vouchers for patients

·       Offer telehealth and bundled appointments to limit time away from work and need for childcare

·       Improve facilities to allow for work conducive areas (Wi-Fi in waiting areas and infusion centers; quiet rooms)

·       Expand hours of care

·       Offer on-site childcare services

·       Expand food, transportation, lodging services

Healthcare Provider Provider education

·       Decrease low value care via national guidelines like Choosing Wisely6

·       Train care team members to collaborate with financial navigators and utilize lower cost sites of care and/or lower OOP cost services; promote conversations about expected and potential unexpected costs

Patient Patient education

·       Catalogue and distribute financial support resources

·       Encourage visit companions (engage family/friends)

·       Provide accessible personnel to answer questions

·       Create survivorship plans that acknowledge financial concerns

Secondary Prevention Clinical Infrastructure Financial toxicity screening

·       Financial harm screening (via validated COST score or single question screening), reassess along cancer treatment path given cumulative burdens

·       Support shared-decision making for financial friction point decisions

Financial toxicity “tumor boards” ·       Engage all members of the clinical care team (MDs, PharmDs, RNs, LCSWs, financial navigators, medical billing) to meet regularly to conduct holistic needs assessments and review all patients to mitigate financial toxicity
Tertiary Prevention Healthcare Provider Encourage cost conversations when appropriate

·       Discuss financial cost-benefit of medications and potential alternatives with a focus on patient priorities via shared-decision making

·       Provide reassurance that care teams and the health system will remain present for patient even in difficult times (e.g. loss of job, loss of insurance) and connect patients to appropriate resources

·       Provide information on alternative pharmacy cost containment mechanisms (GoodRx, Cost Plus Drugs)

Pharmacy Proactive pharmacy assistance

·       Start pharmacy assistance for expensive medications at the time of prescription

·       Alert cancer team to prescribe less costly alternatives via EMR programs sharing patient-specific formulary and out of pocket cost estimates

·       Provide estimates of medication regimen over time for chronic conditions

Click here to view table as PDF

References

  1. National Cancer Opinion Survey (2021) ASCO.https://society.asco.org/research-data/reports-studies/national-cancer-opinion-survey Accessed: April 3, 2024.
  2. National Cancer Institute, Financial Toxicity and Cancer Treatment (PDQ®)–Health Professional Version: https://www.cancer.gov/about-cancer/managing-care/track-care-costs/financial-toxicity-hp-pdq
  3. Zafar SY. Financial Toxicity of Cancer Care: It’s Time to Intervene. J Natl Cancer Inst. May 2016;108(5)doi:10.1093/jnci/djv370
  4. Bradley CJ, Yabroff KR, Shih YT. A Coordinated Policy Approach to Address Medical Financial Toxicity. JAMA Oncol. Dec 1 2021;7(12):1761-1762. doi:10.1001/jamaoncol.2021.3606
  5. COST FACIT Questionnaire: https://www.facit.org/measures/FACIT-COST
  6. Choosing Wisely (2021) ASCO. https://society.asco.org/news-initiatives/current-initiatives/cancer-care-initiatives/value-cancer-care/choosing-wisely. Accessed: April 3, 2024